The Small Molecule Screening and Synthesis Facility (SMSSF) provides UWCCC members with access to high throughput screening (HTS) instrumentation, chemical and RNAi libraries, synthetic chemistry, computational molecular modeling, virtual screening and expert staff. These are all critical activities for early stage discovery of new anti-cancer drugs. By providing infrastructure and expertise that is not available in individual member laboratories, the SMSSF enables UWCCC members to initiate and implement projects focused on the discovery and development of new anti-cancer agents, as well as the characterization of new drug targets. During the past five years, 50 members from seven of the eight Scientific Programs in the UWCCC have used the SMSSF for their research. The data generated at SMSSF has contributed to over 47 publications from UWCCC members and more than 40 funded grants. During the past five years the SMSSF successfully added three new services: screening of a human genome-wide RNAi library, synthetic chemistry for producing analogs or for scale-up and virtual screening.

Public Health Relevance

New safe and effective drugs are needed to treat human cancers. UWCCC members are able to initiate novel drug discovery projects because the Small Molecule Screening and Synthesis Facility provides access to infrastructure and expertise in drug discovery and to chemical and RNAi libraries that are not available in individual academic laboratories.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
United States
Zip Code
Oberley, Christopher C; Bilger, Andrea; Drinkwater, Norman R (2015) Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Mol Carcinog 54:959-70
Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill et al. (2015) A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1?,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract 21:416-24
Kolesar, Jill M; Pomplun, Marcia; Havighurst, Tom et al. (2015) Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract 21:128-31
Simoncic, Urban; Perlman, Scott; Liu, Glenn et al. (2015) Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 13:e7-e17
Zhao, Z; Wang, L; Xu, W (2015) IL-13R?2 mediates PNR-induced migration and metastasis in ER?-negative breast cancer. Oncogene 34:1596-607
Chakravarty, Rubel; Hong, Hao; Cai, Weibo (2015) Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature. Curr Drug Targets 16:592-609
Wu, Jianqiang; Salva, Katrin A; Wood, Gary S (2015) c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death. J Invest Dermatol 135:861-8
LoConte, Noelle K; Razak, Albiruni R A; Ivy, Percy et al. (2015) A multicenter phase 1 study of ? -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs 33:169-76
Romens, Sarah E; McDonald, Jennifer; Svaren, John et al. (2015) Associations between early life stress and gene methylation in children. Child Dev 86:303-9
Nihal, Minakshi; Ahmad, Nihal; Wood, Gary S (2014) SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle 13:632-40

Showing the most recent 10 out of 472 publications